ArticleScientific reports2023
Comparison between an SGLT2 inhibitor and insulin in tumor-to-tissue contrasts in
Liang Meidai, Du Yujing, Liu Zhaoyu, Li Shanshi, Zhao Guangyu, Fan Yan, Yang Xiuying, Zhang Jianhua
Open access · goldAbstract read
In one paragraphArticle in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors at 3 institutions in 1 country.
Liang Meidai *Department of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, People's Republic of China.
Du Yujing *Department of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, People's Republic of China.
Liu ZhaoyuBeijing Key Laboratory of Drug Target and Screening Research, Institute of Materia Medica of Peking, Union Medical College, Beijing, 100050, People's Republic of China.
Li ShanshiDepartment of Radiation Oncology, Peking University First Hospital, Beijing, 100034, People's Republic of China.
Zhao GuangyuDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, People's Republic of China.
Fan YanDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, People's Republic of China.
Yang XiuyingBeijing Key Laboratory of Drug Target and Screening Research, Institute of Materia Medica of Peking, Union Medical College, Beijing, 100050, People's Republic of China. lucia@imm.ac.cn.
Zhang JianhuaDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, People's Republic of China. zjh@bjmu.edu.cn.
Peking University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNPeking University First Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Diabetes Mellitus, ExperimentalNeoplasmsSodium-Glucose Transporter 2 InhibitorsAnimalsBenzhydryl CompoundsFluorodeoxyglucose F18GlucosidesHumansInsulinMiceMice, Inbred C57BLPositron-Emission TomographyBenzhydryl CompoundsdapagliflozinFluorodeoxyglucose F18GlucosidesInsulinSodium-Glucose Transporter 2 Inhibitors
Identifiers
PMID37884546
PMCPMC10603037
OpenAlexW4387958511
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390